




RealRate

PHARMACEUTICAL 2026

Eton Pharmaceuticals Inc
Rank 107 of 178

eTon PHARMACEUTICALS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Eton Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Eton Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 27% points below the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	60,581	Assets	92,114
Cost of Goods Sold	37,210	Liabilities	65,960
Intangible Assets	30,878	Expenses	80,837
Liabilities, Current	38,490	Revenues	79,950
Liabilities, Non-Current	27,470	Stockholders Equity	26,154
Other Assets	329	Net Income	-4,601
Other Compr. Net Income	0	Comprehensive Net Income	-4,601
Other Expenses	43	BaseVar	161,288
Other Liabilities	0	ECR before LimitedLiability	66%
Other Net Income	-3,714	Economic Capital Ratio	202%
Other Revenues	79,950		
Property and Equipment	326		
Research and Development	7,765		
Selling, General and Administrative Expense	35,819		